N@N

51.14% Of All NASDAQ Trading Friday Was Short Selling. PMRY, CBEY, ATSI, CNMD, IMGN, HSII Highest % Of Daily Trading Volume Sh

^{Published on 2009-10-17 11:17:07, Last Modified on 2010-12-22 17:09:50 - WOPRAI}
 

October 19, 2009 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Friday, October 16th, 2009 and come to the following statistical conclusions. There were 6,788 stocks with daily short volume reported and total NASDAQ trading volume of 1,760,962,991 shares. Total Daily Short Volume was 900,691,916 shares. 51.14% of all trading on the NASDAQ Friday was short selling. The chart below highlights 6 stocks that had unusually high percentages of their total daily trading volume attributed to short sales. Pomeroy IT Solutions (NASDAQ: PMRY), Cbeyond (NASDAQ: CBEY), ATS Medical (NASDAQ: ATSI), CONMED Corp (NASDAQ: CNMD), Immunogen (NASDAQ: IMGN) and Heidrick and Struggles (NASDAQ: HSII). To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.buyins.net.

DATE SYMBOL SHORT VOLUME TOTAL VOLUME MARKET PERCENT

20091016 PMRY 124,269 127,866 Q 97.19%

20091016 CBEY 78,216 92,938 Q 84.16%

20091016 ATSI 76,080 91,304 Q 83.33%

20091016 CNMD 65,595 80,260 Q 81.73%

20091016 IMGN 126,660 159,933 Q 79.20%

20091016 HSII 62,214 78,723 Q 79.03%

In late October 2008 the SEC updated Regulation SHO requiring that all short sellers must locate, borrow and deliver any shares they have shorted, no exceptions, by T+3 settlement date. If not, a buy-in must be forced by the broker dealer that the short seller transacted through by the opening of the market on T+4. Since a company first appears on the naked short list when short sellers have been failing to deliver for 5 consecutive trading days, stocks should theoretically never be on the naked short list again. BUYINS.NET will monitor the exchangesa� naked short lists daily and issue an alert and notify the SEC and FINRA should short sellers fail to deliver on any short sales.

Reg SHO Rule 204 (i) requires brokers to deliver shares on long and short sales of publicly traded equity securities by settlement date, (ii) continues to require brokers to close-out fails to deliver by the beginning of trading on T+4 for short sales and T+6 for long sales, (iii) precludes clearing brokers and their introducing brokers from selling short a security, other than on a pre-borrowed basis, if a fail to deliver in that security is not timely closed out until the fail is closed out and that close-out transaction settles, (iv) allows clearing brokers to allocate fails to introducing brokers and (v) continues to permit brokers to rely upon pre-fail credit to satisfy Rule 204's close-out requirement to avoid the pre-borrow requirements when a fail at a clearing broker has not been closed out. However, the SEC liberalized certain of these provisions in several regards. For example, permanent Rule 204 now allows a broker to close-out a fail on a long sale by borrowing the security, whereas Rule 204T had only permitted closing out long fails by buying-in, which should alleviate some of the buy-in risk for investors that experience long fails. Similar relief was extended to close-outs for market maker fails, so that a fail from a bona fide market making transaction (including short and long fails) can now be closed out by the beginning of trading on T+6 by borrowing the security. Further, Rule 204 now permits a broker to borrow securities to obtain pre-fail credit for early close-outs, whereas temporary Rule 204T only permitted pre-fail credit to be obtained by purchases of securities.

The SEC refused requests to extend the close-out deadline for fails to deliver to the close of business on the close-out deadline, choosing instead to retain the requirement that all fails be closed out by the beginning of trading on the applicable close-out deadline. The Commission also rejected requests for a fail to deliver exception that would have provided an exception from the close-out requirements if a clearing broker's fail position was below a certain amount but said that it would continue to monitor whether a de minimis or odd lot exception could be warranted.

Pomeroy IT Solutions, Inc. (NASDAQ: PMRY) provides information technology solutions (IT) in the United States. It offers a range of hardware, software, and technical staffing services, as well as infrastructure and lifecycle services. The companya�s services include IT outsourcing and out-tasking services, which comprise desktop and mobile computing, and server and network environments; and supply chain management services consisting of product acquisition, product distribution, asset management, advanced integration, end-of-life services, and software licensing and logistics services. Its services also comprise systems integration services, which include blade server technologies, storage technologies, network and IP technologies, information security, and operating system technologies that enable clients to plan, design, deploy, and manage technology infrastructures; and technical staffing sourcing, which supports clientsa� project requirements. Pomeroy IT Solutions serves enterprise clients, mid-size businesses, state and local government entities, educational institutions, and vendor alliance customers. The company was formerly known as Pomeroy Computer Resources, Inc. and changed its name to Pomeroy IT Solutions, Inc. in 2003. Pomeroy IT Solutions was founded in 1981 and is based in Hebron, Kentucky.

Cbeyond, Inc. (NASDAQ: CBEY) provides managed Internet protocol-based communications services to small businesses in the United States. Its services include local and long distance voice services, broadband Internet access, mobile voice and data, email, voicemail, Web hosting, secure backup and file sharing, fax-to-email, virtual private network, and other communications and information technology(IT) services. The company also offers mobile voice and data services in conjunction with its landline-based services via its mobile virtual network operator relationship with a nationwide wireless network provider. It offers its services through direct sales force, as well as through channel partners, including value-added resellers, local area network consultants, and other IT and telecommunications consultants. The company was formerly known as Cbeyond Communications, Inc. and changed its name to Cbeyond, Inc. in July 2006. Cbeyond was founded in 2000 and is headquartered in Atlanta, Georgia.

ATS Medical, Inc. (NASDAQ: ATSI) engages in the development, manufacture, and marketing of medical devices for the treatment of structural heart diseases. It offers prosthetic heart valves, such as ATS Open Pivot Heart Valve, a mechanical heart valve, as well as ATS 3F Aortic Bioprosthesis, a biological replacement aortic heart valve; and heart valve repair products, such as ATS Simulus Flexible annuloplasty repair rings and bands, ATS Simulus Semi-Rigid Annuloplasty Ring, and ATS Simulus Adjustable repair rings. The company also markets and sells surgical cryoablation products for the treatment of cardiac arrhythmias, including the ATS CryoMaze Surgical Ablation Probe, the ATS CryoMaze and FrostByte Surgical Ablation Clamps, and the ATS CryoMaze Surgical Ablation Consoles. In addition, it is developing minimally invasive and off-pump aortic valve concepts. The company markets and sells its products through direct sales representatives and agents in the United States, France, Germany, the United Kingdom, Belgium, the Netherlands, and Switzerland; and sells through an independent distributor network to cardiac surgeons throughout the world. ATS Medical, Inc. was founded in 1987 and is based in Minneapolis, Minnesota.

CONMED Corporation (NASDAQ: CNMD), a medical technology company, provides surgical devices and equipment for minimally invasive procedures and monitoring. The companya�s products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, and endosurgery and endoscopic technologies. It offers arthroscopy products, including powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants and related disposable products, and fluid management systems, as well as video endoscopy products, and integrated operating room systems and equipment; powered surgical instruments used to perform orthopedic, arthroscopic, and other surgical procedures; and electrosurgical products comprising electrosurgical pencils and active electrodes, ground pads, generators, and the coagulation systems and smoke evacuation systems. CONMEDa�s patient care products comprise a line of vital signs and cardiac monitoring products, including pulse oximetry equipment and sensors, ECG electrodes and cables, cardiac defibrillation and pacing pads, and blood pressure cuffs; surgical suction instruments and tubing products; and IV products for use in the critical care areas. It also offers endosurgical products, including clip appliers and laparoscopic instruments; and cutting trocars, suction/irrigation accessories, laparoscopic scissors, dissectors and graspers, active electrodes, insufflation needles, and linear cutters and staplers. The companya�s endoscopic technology products include forceps, accessories, bronchoscopy devices, dilatation, hemostasis, biliary devices, and polypectomy for the diagnosis and treatment of gastrointestinal and pulmonary disorders. CONMEDa�s products are used by surgeons and physicians in various specialties, including orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. The company was founded in 1970 and is headquartered in Utica, New York.

ImmunoGen, Inc. (NASDAQ: IMGN) engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Targeted Antibody Payload (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; IMGN901, a Phase I clinical trial product to treat hematological malignancies, including multiple myeloma, small-cell lung cancer, Merkel cell carcinoma, and other cancers of neuroendocrine origin; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkina�s lymphoma; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The companya�s products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; SAR650984, a preclinical trail product to treat hematological malignancies; and TAP and other compounds. It has licensing or collaboration agreements with sanofi-aventis; Genentech, Inc.; Biotest AG; Bayer HealthCare AG; Biogen Idec; Amgen, Inc.; Centocor, Inc.; Cytovance Biologics LLC; Laureate Pharma, Inc.; BioInvent International AB; Diosynth RTP, Inc.; and Societa Italiana Corticosteroidi S.r.l. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.

Heidrick & Struggles International, Inc. (NASDAQ: HSII) provides executive search and leadership consulting services in the Americas, Europe, and the Asia Pacific. It facilitates the recruitment, management, and deployment of senior executives for its clientsa� executive management and board positions. The companya�s leadership consulting services include succession planning, talent retention management, executive assessment, executive development, transition consulting for newly appointed executives, and M&A human capital integration consulting. Its customers include Fortune 1000 companies; the major non-U.S. companies; middle market and emerging growth companies; governmental, higher education, and not-for-profit organizations; and private and public entities. The company was founded in 1953 and is headquartered in Chicago, Illinois.

About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2,650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies or third parties pay $995 per month to purchase data for information provided in monthly reports. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

BUYINS.NET and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of BUYINS.NET, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting BUYINS.NET or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. BUYINS.NET, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to BUYINS.NET and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. BUYINS.NET does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. BUYINS.NET places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.BUYINS.net +1-800-715-9999 Tom@buyins.net